Morning. I'm Anhco Cokey Nguyen, and I am the President and Chief Executive Officer and a member of the board of Atara Biotherapeutics. I'm very happy to welcome you to the Atara Biotherapeutics 2026 Annual Meeting of Shareholders. Before I call the meeting to order, I'd like to introduce to you the members of the board and members of the business team who are with us today via teleconference. The members of the board with us virtually today are Greg Ciangoli, Chair of the Board, Matthew Fust, William Heiden, James Hwang, and Nachi Subramanian. The officers of the company with us virtually today are Yanina Grant-Horta, Chief Accounting Officer, James Cecik, Senior Vice President, Regulatory Affairs, as well as John Chao, our Head of Legal. I would also like to introduce Sean Kennedy of Deloitte & Touche LLP, the company's independent registered public accounting firm, and Carlton Fleming of Sidley Austin LLP, the company's outside legal counsel, who are also in attendance virtually and available to respond to appropriate questions. John Chao, our Head of Legal and Corporate Secretary, will act as secretary for the meeting. The meeting will now officially come to order. The time is 9:01 A.M. Pacific Time on June 9th, 2026. The polls are now open for voting on all matters to be presented. The polls will be closed to voting after we go through the matters to be voted on. As you know, we are hosting today's meeting through a virtual online platform hosted by Broadridge Financial Solutions. This meeting is being recorded and will be archived for one year after the date of meeting at this meeting site, virtualshareholdermeeting.com, and look for Atara 2026. We will proceed with the formal business of the meeting in the order set forth in your notice of annual meeting and proxy statement. We will first present the four proposals submitted for approval. Please save all questions related to the proposals for after all of the proposals have been presented, after which we will announce the preliminary results of the voting. As I mentioned earlier, the polls are open for voting on all matters presented. After I describe each item to be voted on, we will take questions germane to the proposals, if any. Thereafter, we will close the polls. We will not accept ballots, proxies, revocations, or changes after the closing of the polls. If you have already submitted your vote by proxy and do not wish to change your vote, you do not need to vote now. Your shares will be voted as previously instructed. If you intend to vote and have not already done so, you must submit your vote online now in order for it to be counted. If you've not voted, I encourage you to vote online now by logging into the meeting website as a stockholder using the 16-digit control number you received with your proxy materials and clicking the link provided on the screen. Following the conclusion of the formal part of our meeting, if we have time, we will try to answer appropriate questions submitted. Stockholders who are attending this meeting with a valid 16-digit control number can submit questions through the text box located on your screen. Guests to the meeting will not be able to ask questions. Will the secretary of this meeting please report at this time with respect to the mailing of the notice of the annual meeting and the stockholders' list? I have at this meeting a complete list of the stockholders of record of the company's common stock on April 14th, 2026, the record date for this meeting. The list has been available for examination by any stockholder for purposes germane to the meeting during ordinary business hours at our corporate headquarters for the past 10 days and is available for inspection during this meeting for any reason germane to this meeting. If you wish, please click on the link on your online portal to view the list. I also have an affidavit dated May 8th, 2026, certifying that on April 27th, 2026, a notice of the annual meeting of stockholders of the company was deposited in the United States mail to all stockholders of record at the close of business on April 14th, 2026. At this time, I am appointing Carlton Fleming of Sidley Austin LLP to act as the Inspector of Election at this meeting. Mr. Fleming has taken and subscribed to the customary oath of office to execute his duties with strict impartiality. We will file this oath with the records of the meeting. His function is to decide upon the qualifications of voters, accept their votes, and when balloting on all matters is completed, to tally the final votes. Will the secretary please report at this time with respect to the existence of a quorum? I have been informed by the Inspector of Election that proxies have been received for 6,521,052 of the 8,512,272 shares of common stock outstanding on the record date, which represents approximately 76% of the total number of outstanding shares. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting. There are four proposals to be considered by stockholders at this meeting. The first item of business is the election of two directors to serve until the 2029 annual meeting of stockholders and until their successors are elected. The nominees for directors are Anhco Nguyen and Nachi Subramanian. The second item of business today is the proposal to approve, on an advisory basis, the compensation paid to the company's named executive officers as described in the proxy statement. The stockholders have been asked to vote on an advisory basis on the following resolution. Resolved, that the compensation paid to the company's named executive officers as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, Compensation tables and narrative discussion that accompanies the compensation tables is hereby approved. The third item of business today is the proposal to approve the first amendment to the company's 2024 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 400,000. The fourth item of business today is the ratification of the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31st, 2026. That was the final proposal for today's meeting. There are no questions. The time is now 9:07 A.M. on June 9th, 2026, the polls are now closed for voting. May we have the preliminary results of the voting? The report of the Inspector of Election covering the proposals presented at this meeting is as follows: The proposal to elect Anhco Nguyen and Nachi Subramanian as directors of the company is carried. The resolution concerning the advisory vote on the executive compensation of the company's named executive officers is approved. The proposal to approve the first amendment to the company's 2024 Equity Incentive Plan to increase the number of shares of common stock reserved thereunder by 400,000 is approved. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31st, 2026 is ratified. A full tally of the final voting results will be published in a current report on Form 8-K, which will be filed with the Securities and Exchange Commission within four business days of this meeting. This concludes the formal portion of today's meeting. It appears there are no additional questions. Thank you again for your attendance at today's meeting and for your continued support of Atara Biotherapeutics. This meeting is concluded. This concludes today's meeting. Thank you for attending. You may now disconnect and have a wonderful rest of your day.